Please assess the completion status of the following clinical trial:

Trial Title: TMC207-TiDP13-C208: Anti-bacterial Activity, Safety, and Tolerability of TMC207 in Participants With Multi-drug Resistant Mycobacterium Tuberculosis (MDR-TB).

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Females of non-childbearing potential~* Patients with newly diagnosed sputum smear-positive pulmonary MDR-TB infection~* Patients must consent to HIV-testing~* Patients must be willing to discontinue all TB drugs to allow 7 days washout~* Patients having normal weight~* Patients are willing to be hospitalized per standard of care.~Exclusion Criteria:~* Previously having been treated for MDR-TB~* Having a significant cardiac arrhythmia that requires medication~* For HIV infected patients, having a CD4+ count \< 300 cells/µL~* Patients with complicated or severe extrapulmonary manifestations of TB or neurological manifestations of TB~* Patients who will require surgical procedure for management of their TB~* Evidence of chorioretinitis, optic neuritis, or uveitis at screening~* Having had a drug susceptibility test performed prior to screening and being not susceptible to at least 3 of the 5 classes of TB drugs used to treat MDR-TB~* Women who are pregnant and/or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- TMC207 Stage 1 (Type: EXPERIMENTAL): TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 weeks in addition to Background Regimen (BR) for multi-drug resistant tuberculosis (MDR-TB).
- Placebo Stage 1 (Type: PLACEBO_COMPARATOR): Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 weeks in addition to BR for MDR-TB.
- TMC207 Stage 2 (Type: EXPERIMENTAL): TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 22 weeks in addition to BR for MDR-TB.
- Placebo Stage 2 (Type: PLACEBO_COMPARATOR): Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 22 weeks in addition to BR for MDR-TB.

Based on this trial design, predict the completion outcome and termination type (if applicable).